Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
02/14/202511:10AMBusiness WireIMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trialNASDAQ:AZNAstraZeneca PLC
02/13/20255:45AMPR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
02/10/20255:45AMPR Newswire (US)Investors who lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
02/06/20259:53AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
02/06/20257:00AMBusiness WireAstraZeneca’s Full Year and Q4 2024 resultsNASDAQ:AZNAstraZeneca PLC
02/06/20255:45AMPR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
02/06/202512:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AZNAstraZeneca PLC
02/03/20251:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
02/03/20256:23AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
02/03/20255:45AMPR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
01/30/20255:45AMPR Newswire (US)AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AZNAstraZeneca PLC
01/27/20256:00PMBusiness WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapiesNASDAQ:AZNAstraZeneca PLC
01/27/20255:45AMPR Newswire (US)Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
01/23/20252:33PMPR Newswire (Canada)AstraZeneca prévoit un investissement de 820 M$ CA (570 M$ US) au Canada pour consolider son statut grandissant de plaque tournante mondiale et faire progresser la réalisation d'essais cliniquesNASDAQ:AZNAstraZeneca PLC
01/23/20252:32PMPR Newswire (Canada)AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical deliveryNASDAQ:AZNAstraZeneca PLC
01/23/20255:45AMPR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
01/23/20255:00AMPR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
01/20/20255:45AMPR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
01/17/20255:35PMBusiness WireDATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
01/17/20257:00AMBusiness WireCALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphomaNASDAQ:AZNAstraZeneca PLC
01/16/20255:45AMPR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
01/13/20257:00AMBusiness WireDatopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
01/13/20255:45AMPR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
01/09/20255:45AMPR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
01/02/20251:50PMPR Newswire (US)AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZNNASDAQ:AZNAstraZeneca PLC
01/02/202510:42AMPR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
12/30/20245:45AMPR Newswire (US)Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact The Gross Law FirmNASDAQ:AZNAstraZeneca PLC
12/18/20249:05AMPR Newswire (Canada)Alexion, la division des maladies rares d'AstraZeneca, et l'Alliance pharmaceutique pancanadienne (APP) parviennent à un accord au sujet de Koselugo (sélumétinib) pour le traitement des enfants atteints de neurofibromatose de type 1 (NF1) présentant deNASDAQ:AZNAstraZeneca PLC
12/18/20249:05AMPR Newswire (Canada)Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform nNASDAQ:AZNAstraZeneca PLC
12/11/202410:15AMBusiness WireLYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trialNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN